Asian Currencies Steady as Markets Await U.S. Inflation Data 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
ADNOC Gas Targets Up to $4B Profit in 2026 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
